PARAGUAY

Cutaneous and mucosal Leishmaniasis 2018

Incidence (100,000 pop.)

5.88

Transmission

Triennium Leishmaniasis Composite Indicator (TLCIc 2016-2018)

 $ILOV_{N}$

Occurrence

NEW CASES

32 cutaneous (38.1%)

52 mucosal (61.9%)

TLCIc triennium

(2016-2018)


4.13 - 9.49 (Very intense)

2.05 - 4.12 (Intense)

0.34 - 2.04 (High)

-0.76 - 0.33 (Moderate)

-1.59 - -0.77 (Low)





AGE GROUP

1.2% < 5 Y/O

1.2% children



GENDER

81% Male 19% Female

81% men over 20 vears old



CROSS-BORDER

Shares borders with 03 countries in 22 municipalities

29.8% of the cases at the borders



SURVEILLANCE AND CONTROL

21.6% of the population in transmission areas

Increase of the CL % in children under 10 Y/O compared to the previous year (Targets of the 2017-2022 Plan of Action)



LEISHMANIA **SPECIES**



LUTZOMYIA VECTORS

L. migonei

L. neivai

L. pessoai

L. shannoni

L. whitmani



PATIENT ASSISTANCE

Laboratory confirmation: 100%

Cure rate: **78.6%**

% of cured patients among the treated: 78.6%



AVAILABLE MEDICINE

Meglumine Antimoniate

Amphotericin B Liposomal

Amphotericin B deoxycholate

Source:

SisLeish - PAHO/WHO - Data provided by the Ministries of Health -National Leishmaniasis Programs Accessed on: 01 November 2019. N/I: No information available; Y/O: years old





PARAGUAY

Visceral Leishmaniasis 2018

Incidence (100,000 pop.)

1.47

Transmission

Triennium - Visceral Leishmaniasis Composite Indicator (TLCIv 2016-2018)

Moderate

Occurrence

19

NEW CASES
OF VISCERAL
LEISHMANIASIS

TLCIv triennium

(2016-2018)

3.75 - 5.57 (Very intense)

1.68 - 3.74 (Intense)

0.35 - 1.67 (High)

-0.59 - 0.34 (Moderate)

-1.17 - -0.60 (Low)



AGE GROUP

26.3% < 10 Y/O 36.9% ≥ 10 < 50 Y/O

21% children under 5 years old



GENDER

57.9% Masculino 42.1% Femenino

52.6% men over 20 years old



FATALITY

02 deaths by visceral leishmaniasis

10.5% fatality rate

50% of the deaths in ≥ 50 years old



PATIENT ASSISTANCE

Laboratory confirmation: **100%**

Cure rate: **73.7%**

% of cured patients among the treated: **73.7%**



LEISHMANIA SPECIE

L. infantum



LUTZOMYIA VECTORS

L. longipalpis



SURVEILLANCE

Transmission in **expansion**

Urban/Rural domestic cycle

Domestic reservoir: **Dog**



AVAILABLE MEDICINE

Meglumine Antimoniate

Amphotericin B Liposomal

Amphotericin B deoxycholate

Source:

SisLeish - PAHO/WHO - Data provided by the Ministries of Health - National Leishmaniasis Programs Accessed on: 01 November 2019. N/I: No information available; Y/O: years old

Pan American Health Organization

